Cardarine protocol

The published research protocols cluster around 2.5–10 mg per day for 4–12 weeks, with most rodent-equivalent dosing translating to the lower end of that range. But there is no validated human protocol because clinical development stopped after long-term animal studies linked GW-501516 to accelerated tumor growth across multiple organ systems.

The Most Cited Dosing Range Comes From Abandoned Human Trials

The two published clinical trials that reached peer review tested 2.5 mg, 5 mg, and 10 mg doses daily over 2–12 weeks in small cohorts of metabolic syndrome patients. These studies reported dose-dependent changes in HDL cholesterol and triglycerides without reported severe adverse events during the trial windows. GlaxoSmithKline terminated development in 2007 after internal toxicology studies — conducted at doses and durations that mirror chronic human use — showed reproducible increases in tumor incidence in rats across liver, stomach, tongue, bladder, and other tissues.

What circulates in performance and research communities as a "standard protocol" — typically 10–20 mg per day for 8–12 weeks — does not come from controlled human trials. It is extrapolated from the discontinued clinical work, combined with anecdotal reports from non-clinical use. There is no published data validating safety or efficacy at these higher end ranges in humans. The compound is distributed for research purposes only, not human consumption.

The dosing that produced the cancer signal in rodents was 3 mg/kg/day over two years. Adjusted for human equivalent dosing using standard allometric scaling, that translates to roughly 0.5 mg/kg/day in humans, or 35 mg/day for a 70 kg individual — a range that overlaps with what some users report taking.

PPARδ Activation Rewires Cellular Fuel Preference Toward Fat Oxidation

GW-501516 binds to peroxisome proliferator-activated receptor delta (PPARδ), a nuclear receptor abundant in skeletal and cardiac muscle, adipose tissue, and liver. Once the ligand binds, PPARδ heterodimerizes with retinoid X receptor (RXR), translocates to the nucleus, and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes. This transcriptional cascade upregulates genes involved in fatty acid oxidation — including carnitine palmitoyltransferase 1 (CPT1), acyl-CoA oxidase, and uncoupling proteins — while downregulating pathways tied to glucose metabolism.

The result is a metabolic shift. Muscle fibers begin preferentially oxidizing fatty acids instead of glucose. Mitochondrial biogenesis markers increase. In rodent models, this shift correlates with increased running endurance, reduced muscle glycogen depletion, and improved lipid profiles. PPARδ also modulates inflammatory pathways by interfering with NF-κB signaling, which may explain observed reductions in inflammatory markers in some animal studies.

This mechanism is distinct from Sermorelin or Ipamorelin, which act on growth hormone secretagogue pathways. It is also unrelated to androgen receptor biology, despite common misclassification as a SARM.

The Rodent Endurance Data Is Strong; Human Efficacy Data Is Sparse

In vitro PPARδ activation studies show dose-dependent increases in fatty acid oxidation genes across skeletal myocytes and hepatocytes. These findings are consistent across multiple independent labs.

In rodent models, GW-501516 administration produced measurable phenotypic changes. One widely cited 2007 Cell paper showed that sedentary mice given GW-501516 ran 68% longer on treadmill tests compared to controls. A separate study using exercise-trained mice showed that combining the compound with training extended endurance beyond training alone. Other rodent work demonstrated reductions in LDL cholesterol, increases in HDL, reductions in fasting triglycerides, and improved insulin sensitivity in diet-induced obesity models.

Primate studies are limited but showed similar lipid profile improvements. One rhesus macaque study reported HDL increases and triglyceride reductions with 12 weeks of daily dosing.

Human data consists of two small Phase II trials published in 2007 and 2008. The first enrolled 268 subjects with metabolic syndrome; participants received 2.5 mg, 5 mg, or 10 mg daily for 12 weeks. The study reported dose-dependent HDL increases (ranging from 5.4% to 10.1% depending on dose) and triglyceride reductions (10–24%), with minimal effect on LDL or glucose markers. The second trial, shorter in duration, replicated the lipid findings but did not assess endurance or exercise capacity.

No published human trial has tested endurance outcomes. No published human trial has extended beyond 12 weeks. No long-term follow-up data exists for the original trial cohorts.

The Carcinogenicity Data Ended Clinical Development and Raises Unresolved Risk

The strongest limitation is not the absence of large-scale human trials — it is the presence of consistent cancer acceleration signals in long-term rodent toxicology work. Internal GlaxoSmithKline studies — later summarized in regulatory filings and independent reviews — showed that doses of 3 mg/kg/day over 104 weeks in rats produced statistically significant increases in tumor incidence across multiple organ sites. Tumors appeared in the liver, stomach, tongue, skin, bladder, and other tissues. The findings were dose-dependent and reproducible.

A 2009 review published in Toxicological Sciences examined the preclinical data and concluded that PPARδ activation at sustained high levels promotes cell proliferation and inhibits apoptosis in ways that may facilitate tumorigenesis in tissues already carrying oncogenic mutations or precancerous lesions. The exact mechanism linking PPARδ agonism to cancer remains debated, but hypotheses include dysregulation of cell cycle checkpoints and altered prostaglandin signaling.

No comparable long-term human safety data exists. The published human trials lasted weeks, not years. Whether the cancer risk observed in rodents translates to humans at typical self-administered doses is unknown. Some researchers have argued that rodent PPARδ tissue distribution differs from humans, which might alter risk translation — but this has not been validated.

The compound was added to the World Anti-Doping Agency (WADA) prohibited list in 2009 despite never completing clinical development. Regulatory agencies in multiple countries have issued warnings specifically naming GW-501516 due to cancer risk.

A second limitation is the lack of clarity around dose-response curves in humans. The clinical trials tested up to 10 mg daily, but anecdotal protocols often report 15–20 mg. There is no data on whether higher doses produce proportionally greater lipid or endurance effects, or whether they increase toxicity risk nonlinearly.

A third limitation is interaction data. GW-501516 is often stacked with other research compounds — MK-677, BPC-157, or androgenic compounds — with no controlled studies on combined metabolic or safety effects.

FAQ

Q: What dosing schedule appears most often in published human trials?

The two Phase II trials used once-daily oral dosing at 2.5 mg, 5 mg, or 10 mg, taken in the morning with or without food. The compound has a half-life of approximately 16–24 hours in humans based on limited pharmacokinetic data, which supports once-daily dosing. No published study tested twice-daily split dosing, though some research use reports describe dividing the dose.

Q: How long does it take to see metabolic changes in the available human data?

In the 12-week metabolic syndrome trial, statistically significant HDL increases were detectable by week 6, with further increases by week 12. Triglyceride reductions followed a similar timeline. No human trial measured exercise endurance or time-to-effect for performance outcomes. Rodent endurance improvements appeared within 3–4 weeks of daily dosing, but cross-species timelines do not translate directly.

Q: Is there a validated post-cycle or washout protocol?

No. The clinical trials did not include formal washout periods or structured discontinuation protocols. One pharmacokinetic analysis suggested that plasma levels return to baseline within 48–72 hours after stopping, but downstream gene expression changes — particularly in PPARδ-regulated pathways — may persist longer. There is no published data on rebound metabolic effects, lipid changes, or endurance loss after stopping.

Q: Does GW-501516 suppress endogenous hormone production like androgenic compounds?

No evidence suggests that GW-501516 affects the hypothalamic-pituitary-gonadal axis or suppresses testosterone, luteinizing hormone, or follicle-stimulating hormone. It does not bind androgen receptors. Lipid and metabolic changes occur independently of hormonal signaling pathways targeted by anabolic agents. This is one reason it is sometimes used in research contexts where androgen suppression is a concern — though the cancer risk remains regardless of hormonal interaction.

Q: Are there liver toxicity markers to monitor during a research protocol?

The published human trials reported no clinically significant changes in liver enzymes (ALT, AST) at doses up to 10 mg daily over 12 weeks. However, rodent carcinogenicity data included hepatic tumors, and long-term human hepatotoxicity has not been ruled out. Any extended research protocol would reasonably include baseline and periodic liver function testing, though there is no formal monitoring guideline. Lipid panels were the primary endpoints in the clinical trials and would be the most relevant marker for tracking pharmacological activity.

---

This article is for informational and research purposes only. GW-501516 is not approved for human use by any regulatory agency and has been specifically flagged for cancer risk in animal studies. Any research use should be conducted under appropriate oversight and with full awareness of incomplete human safety data.